Skip to main content
Download PDF

Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p

Cancer Cell International volume 21, Article number: 638 (2021) Cite this article

Abstract

Background

The emergence of chemoresistance to 5-fluorouracil (5-FU)-based chemotherapy is the main cause of treatment failure in advanced and metastatic colorectal cancer (CRC) patients. Long noncoding RNAs (lncRNAs) have been reported to be involved in 5-FU resistance. Previously, we first detected that lncRNA cetuximab resistance-associated RNA transcript 16 (CRART16) could contribute to cetuximab resistance by upregulating V-Erb-B2 erythroblastic leukemia viral oncogene homologue 3 (ERBB3) expression by sponging miR-371a-5p in CRC cells. The current study aimed to explore the role of CRART16 in acquired 5-FU resistance in CRC cells and its possible mechanism.

Methods

Quantitative real-time PCR (RT-qPCR) was used to measure the expression levels of CRART16 in a 5-FU-resistant CRC cell subline (SW620/5-FU) and the parent cell line. Lentivirus transduction was performed to establish SW620 and Caco-2 cells stably overexpressing CRART16. Cell Counting Kit-8 (CCK-8) assays and colony formation assays were applied to measure cell chemosensitivity to 5-FU. Flow cytometric and immunofluorescence staining were adopted to assess cell apoptosis induced by 5-FU. The dual-luciferase reporter assay was used to validate the direct interactions between CRART16 and miR-193b-5p and between miR-193b-5p and high-mobility group AT-hook-2 (HMGA2). The expression levels of HMGA2, apoptosis-associated proteins and p-ERK were examined by western blotting. The statistical differences within any two groups were used Student’s t test.

Results

CRART16 was upregulated in SW620/5-FU cells. Overexpression of CRART16 reduced the sensitivity of CRC cells to 5-FU by attenuating apoptosis. In addition, CRART16 promoted 5-FU resistance by suppressing the expression of miR-193b-5p. Furthermore, CRART16 modulated the expression of HMGA2 by inhibiting miR-193b-5p and activated the MAPK signaling pathway.

Conclusions

CRART16 confers 5-FU resistance in CRC cells through the CRART16/miR-193b-5p/HMGA2/MAPK pathway.

Background

Colorectal cancer (CRC) is among the most common cancers worldwide, ranking third in terms of incidence but second in terms of mortality [1]. After decades of research and development, comprehensive treatment based on surgical resection has become the main treatment mode of CRC; the involved approaches include endoscopic and surgical local excision, adjuvant chemotherapy, downstaging preoperative chemoradiotherapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metastases, palliative surgery and chemotherapy, targeted therapy, and immunotherapy. Among them, drug therapy has developed the most rapidly, significantly improving the prognosis of advanced and metastatic colorectal cancer (mCRC) patients [2]. Despite the fact that research has entered into the era of targeted therapy and immunotherapy, 5-fluorouracil (5-FU) is still the first-line drug and plays an irreplaceable role in the treatment of advanced CRC and mCRC [3].

5-FU, an analogue of uracil that was first synthesized by Heidelberger et al. [4] in 1957, eventually inhibits the synthesis of purines by inhibiting thymidylate synthase (TS) activity in vivo, resulting in the inhibition of DNA replication and repair. In addition, the incorporation of 5-FU-derived nucleosides into RNA fractions interferes with RNA synthesis and function [5]. However, it has been documented that a considerable percentage of CRC patients and nearly half of mCRC patients experience disease progression during the course of 5-FU-based chemotherapy [6, 7]. Both primary and acquired chemoresistance are responsible for treatment failure and limit the clinical application of 5-FU [8]. Although many efforts have been made to reveal the molecular mechanisms underlying chemoresistance to 5-FU in CRC, novel therapeutic targets have yet to be identified.

As new potential regulators in various cellular processes, long noncoding RNAs (lncRNAs), noncoding RNAs (ncRNAs) withs length longer than 200 nucleotides and without protein-coding capacity, have recently attracted growing interest in different cancer types [9]. Several studies have indicated that some lncRNAs play an important role in drug resistance [10,11,12,13]. LncRNA UCA1 has been reported to contribute to cisplatin/gemcitabine resistance in vitro and vivo via CREB, which modulates miR-196b-5p in bladder cancer [14]. Similarly, lncRNA XLOC_006753 has been proven to promote multidrug resistance in vitro via the PI3K/AKT/mTOR signaling pathway in gastric cancer [15]. To date, few studies have focused on lncRNAs in CRC 5-FU chemoresistance [16]. Previously, we first found that lncRNA cetuximab resistance-associated RNA transcript 16 (CRART16) promotes cetuximab resistance by enhancing V-Erb-B2 erythroblastic leukemia viral oncogene homologue 3 (ERBB3) expression through miR-371a-5p in CRC cells [17]. However, the role of lncRNA CRART16 in CRC cell 5-FU resistance needs to be further investigated.

In this study, we found that the expression level of CRART16 was upregulated in SW620/5-FU cells. Further mechanistic investigation demonstrated that when it was overexpressed, CRART16 enhanced the 5-FU resistance of CRC cells and upregulated high-mobility group AT-hook-2 (HMGA2) expression by sponging miR-193b-5p. Moreover, we revealed that the MAPK signaling pathway was activated by CRART16.

Methods

Cell lines

HEK-293 T and human CRC lines (SW620, Caco-2) were purchased from the Cancer Institute of the Chinese Academy of Medical Science and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher Scientific, MA, USA) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, MA, USA) and 1% penicillin/streptomycin (Thermo Fisher Scientific, MA, USA). The 5-FU-resistant CRC subline (SW620/5-FU) was developed by exposing parental cells to 5-FU in stepwise increasing concentrations for approximately 6 months. SW620/5-FU cells were maintained in DMEM supplemented with 10 μM 5-FU. All cells were grown at 37 °C in an incubator with 5% CO2.

RNA extraction and quantitative real-time PCR (RT-qPCR) analyses

Total RNA was isolated from cultured cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. For miRNA quantification, reverse-transcribed complementary DNA was synthesized from 2 µg extracted total RNA using TransScript miRNA RT Enzyme Mix (Transgen Biotech, Beijing, China) and amplified with TransStart TIP Green qPCR SuperMix (Transgen Biotech, Beijing, China) with normalization to U6. For lncRNA and mRNA detection, RNA was reverse-transcribed with random primers using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, MA, USA) and amplified with PowerUp™ SYBR™ Green Master Mix (Thermo Fisher Scientific, MA, USA) with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. RT-qPCR was performed with a 7500 Real-Time PCR System (Applied Biosystems, Germany). The relative RNA expression levels were calculated with the 2−∆∆Ct method normalized by internal control. The RT-qPCR experiment in this study followed the MIQE guidelines [18]. The primer sequences used in the study are listed in Table 1.

Table 1 Primer sequences used for RT-qPCR
Full size table

Lentivirus transduction

The plasmid pCDH-CMV-MCS-EF1-GFP + Puro containing full-length CRART16 cDNA (Mailgene, Beijing, China) was constructed to stably overexpress the expression of CRART16 in SW620 and Caco-2 cells by lentivirus transduction as we previously described [17]. The cells were named SW620-CRART16 and Caco-2-CRART16, and their negative control cells were called SW620-NC and Caco-2-NC, respectively.

Dual luciferase reporter gene assay

The full-length CRART16 and HMGA2 3′ untranslated regions (3′-UTRs) were inserted into the pmiR-RB-Report™ vector to construct luciferase reporter vectors (RiboBio, Guangzhou, China). HEK-293 T cells were seeded in 96-well plates and cultured overnight. HEK-293 T cells were co-transfected with 0.1 μg WT vector or empty vector and 50 nM miR-193b-5p mimics (RiboBio, Guangzhou, China) or negative controls using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocols. Forty-eight hours after co-transfection, the Dual‐Luciferase Reporter Assay System (Cat. E2920, Promega, Madison, Wisconsin, USA) was used to measure the luciferase activity, and all experiments were carried out in triplicate.

Cell viability assay

For dose–effect curve depiction, the cells were seeded into 96-well plates and cultured overnight, and then the culture medium was replaced with fresh culture medium containing different concentrations of 5-FU. After 48 h of incubation, Cell Counting Kit-8 (CCK-8; Bimake, Shanghai, China) assays were performed to detect cell viability. The optical density at 450 nm was measured using a spectrophotometer at different time points. Each experiment was performed thrice.

Colony formation assay

Transfected cells were seeded (300 cells per well) into 6-well plates and cultured overnight. Then, the culture medium was replaced with fresh culture medium containing 5-FU. The medium was changed every 5 days. After 10–14 days, colonies could be clearly observed. The colonies were fixed with methanol for 15 min and stained with 0.1% crystal violet for 20 min. Then, the colonies were photographed and counted.

Flow cytometry

After treatment with 5-FU for 48 h, the stably transfected CRC cells were digested with DMSO-free trypsin (Invitrogen, Carlsbad, CA, USA) and washed two times with cold PBS. Then, flow cytometry (BD Biosciences, NJ, USA) was carried out after double staining with APC-annexin V and 7-amino-actinomycin D (7-AAD, BD Biosciences, NJ, USA) according to the manufacturer’s protocol.

Western blotting assay and antibodies

Total cellular protein was collected in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing phenylmethylsulfonyl fluoride (PMSF), aprotinin, sodium orthovanadate and NaF. Equal amounts of proteins were subjected to electrophoresis on a SurePAGE gel (GenScript, Nanjing, China) and then transferred onto a polyvinylidene fluoride (PVDF) membrane. The membrane was then blocked in 5% skimmed milk for 1 h at room temperature and incubated with different diluted primary antibodies, including HMGA2 (1:1000 dilution, CST, MA, USA), PARP (1:1000 dilution, CST, MA, USA), cleaved PARP (1:1000 dilution, CST, MA, USA), caspase-3 (1:1000 dilution, CST, MA, USA), cleaved caspase-3 (1:1000 dilution, CST, MA, USA), caspase-7 (1:1000 dilution, CST, MA, USA), cleaved caspase-7 (1:1000 dilution, CST, MA, USA), P-ERK (1:2000 dilution, CST, MA, USA), ERK (1:1000 dilution, CST, MA, USA), tubulin (1:1000 dilution, CST, MA, USA), and GAPDH (1:1000 dilution, CST, MA, USA), at 4 °C overnight. Finally, an enhanced chemiluminescence (ECL) detection system (Merck, Darmstadt, Germany) and the Syngene GeneGenius gel imaging system (Syngene, Cambridge, UK) were used to visualize the protein bands after incubation with secondary antibody.

Immunofluorescence staining

Transfected cells were seeded into 6-well plates placed with coverslips in the bottom and cultured overnight. Then, the culture medium was replaced with fresh culture medium containing 5-FU. After 48 h of incubation, the cells were fixed and permeabilized with a methanol and acetone mixture. After blocking with 10% goat serum, the cells were incubated with primary anti-cleaved caspase-3 (1:100 dilution, CST, MA, USA) or anti-Ki-67 (1:100 dilution, CST, MA, USA) at 4 °C overnight, followed by incubation with secondary Alexa Fluor 555 goat anti-mouse IgG (1:100 dilution, CST, MA, USA) or Alexa Fluor 647 goat anti-rabbit IgG (1:100 dilution, CST, MA, USA) for 1 h. Coverslips were mounted on slides using DAPI. The cells were visualized using a fluorescence microscope.

Statistical analysis

All statistical analyses were performed with SPSS Version 25.0 software (IBM) and GraphPad Prism Version 7 software (GraphPad Software). Data are presented as the mean ± SD. The results were considered statistically significant at p < 0.05. The statistical differences within any two groups were used Student’s t test.

Results

CRART16 expression is upregulated in 5-FU-resistant CRC cells

The expression levels of CRART16 in different CRC cell lines have been shown in our previous published study [17]. To detect whether CRART16 is involved in the acquired resistance of CRC cells to 5-FU, its expression level in a cell line with acquired 5-FU resistance was assessed. The 5-FU-resistant variant SW620/5-FU cell subline was generated by the stepwise screening of SW620 cells exposed continuously to increasing concentrations of 5-FU at a range of 0.1 to 10 µM for approximately 6 months. The CCK-8 assay was applied to confirm the sensitivity of SW620/5-FU and parent cells to 5-FU. Figure 1a shows that the cell viability rate of SW620/5-FU cells was significantly higher than that of SW620 cells when exposed to 5-FU. The half-maximal inhibitory concentration (IC50) value of 5-FU in SW620/5-FU cells was 109.20 ± 12.92 µM, while that in SW620 cells was 47.44 ± 3.17 µM (p < 0.01, Fig. 1b). Then, the expression levels of CRART16 were investigated by RT-qPCR in SW620/5-FU and parent cells. The results demonstrated that the expression of CRART16 was significantly upregulated in SW620/5-FU cells versus parental cells (Fig. 1c), suggesting that CRART16 may participate in 5-FU-acquired resistance in CRC cells.

Fig. 1
figure 1

CRART16 is upregulated in SW620/5-FU cells. a, b The cytotoxic effect of 5-FU was evaluated by CCK-8 assay in SW620 and SW620/5-FU cells after exposure to graded concentrations of 5-FU for 48 h (a), and the IC50 values were calculated (b). **p < 0.01. c The expression levels of CRART16 in SW620 and SW620/5-FU cells were measured by RT-qPCR. GAPDH was used as an internal reference. Data are presented as the mean ± SD from three independent experiments. *p < 0.05

Full size image

Overexpression of CRART16 is associated with 5-FU resistance in CRC cells

To investigate the precise biological function of CRART16 in the 5-FU chemoresistance of CRC cells, we stably overexpressed CRART16 in SW620 and Caco-2 cells. Fluorescence microscopy and RT-qPCR were adopted to confirm the efficiency of transfection (Fig. 2a, b). After treatment with increasing concentrations of 5-FU for 48 h, cell viability was evaluated by CCK-8 assay (Fig. 2c, d). Compared with SW620-NC and Caco-2-NC cells, the IC50 values of 5-FU in CRART16-overexpressing cells were significantly increased by 434.58% and 60.96%, respectively (SW620-NC 4.02 ± 0.79 µM, SW620-CRART16 21.49 ± 0.82 µM, P < 0.001; Caco-2-NC 22.13 ± 2.04 µM, Caco-2-CRART16 35.62 ± 2.6 µM, P < 0.01). We performed a colony formation assay under 5-FU treatment and revealed that after CRART16 was upregulated, the number of cell clones was less suppressed by 5-FU (P < 0.01, P < 0.05, Fig. 2e, f). To further examine whether CRART16 had an effect on 5-FU-induced apoptosis, a flow cytometric assay was performed. The results showed that overexpression of CRART16 in SW620 and Caco-2 cells with 5-FU treatment had lower apoptotic rates than the negative control cells (Fig. 3a, b). Consistently, we observed that the apoptotic marker cleaved caspase-3 was downregulated and the proliferative marker Ki-67 was upregulated in CRART16-overexpressing cells versus negative control cells 48 h after 5-FU treatment (P < 0.05, Fig. 4a, b). Collectively, these data demonstrated that CRART16 could promote 5-FU resistance in CRC cells by attenuating apoptosis.

Fig. 2
figure 2

CRART16 confers 5-FU resistance in CRC cells. a, b Overexpression efficiency in CRART16 in SW620 and Caco-2 cells was validated by fluorescence microscopy (Scale bar: 100 μm) (a) and RT-qPCR (b). ***p < 0.001. c, d The sensitivity of SW620-NC and SW620-CRART16 cells (c) and Caco-2-NC and Caco-2-CRART16 cells (d) to 5-FU was assessed by CCK-8 assay after treatment with increasing concentrations of 5-FU for 48 h. The IC50 values of 5-FU were calculated. Data are presented as the mean ± SD from three independent experiments. ***p < 0.001, **p < 0.01. e, f Effects of CRART16 overexpression on colony formation of CRC cells treated with 5-FU. **p < 0.01, *p < 0.05

Full size image
Fig. 3
figure 3

CRART16 confers 5-FU resistance in CRC cells. a, b The effects of CRART16 overexpression on cell apoptosis were detected by flow cytometry in CRC cells exposed to 5-FU. ***p < 0.001

Full size image
Fig. 4
figure 4

CRART16 confers 5-FU resistance in CRC cells. a, b The effects of CRART16 overexpression on the expression of cleaved caspase-3 and Ki-67 were assessed by immunofluorescence staining (Scale bar: 2 μm). *p < 0.05

Full size image

CRART16 directly binds to miR-193b-5p as a competing endogenous RNA (ceRNA)

Our previously published study demonstrated that CRART16 could confer cetuximab resistance in CRC cells by functioning as a ceRNA [17]. We hypothesized that CRART16 could also promote 5-FU resistance in CRC cells by inhibiting the function of a certain miRNA. Based on the previous work of RNA-seq analysis and bioinformatics prediction, we found that CRART16 harbors several recognition sequences of miR-193b-5p (Fig. 5a). To confirm the potential relationship between CRART16 and miR-193b-5p, luciferase reporter vectors containing full-length CRART16 were constructed for the dual-luciferase reporter assay. We observed that compared with the miRNA negative control group, the miR-193b-5p mimics group showed dramatically reduced luciferase activity for the CRART16-WT reporter vectors but little change in that for the empty vectors (Fig. 5b). In addition, RT-qPCR was performed to assess the expression levels of miR-193b-5p, and the results showed that the expression levels of miR-193b-5p were significantly downregulated in CRART16-overexpressing cells and SW620/5-FU cells compared with the corresponding control cells (Fig. 5c). Taken together, these results revealed that the expression of miR-193b-5p was negatively regulated by CRART16 through direct binding. We further performed a rescue experiment to evaluate the function of miR-193b-5p in 5-FU resistance induced by CRART16 overexpression. The CCK-8 assay revealed that ectopic miR-193b-5p expression significantly reversed CRART16-induced 5-FU resistance in both SW620-CRART16 and Caco-2-CRART16 cells (SW620-CRART16 + NC 21.07 ± 2.79 µM, SW620-CRART16 + miR-193b-5p mimics 11.02 ± 0.86 µM, p < 0.05; Caco-2-CRART16 + NC 48.67 ± 2.98 µM, Caco-2-CRART16 + miR-193b-5p mimics 26.41 ± 3.0 µM, p < 0.01) (Fig. 5d, e). Collectively, these results demonstrated that CRART16 promoted 5-FU resistance by suppressing the expression of miR-193b-5p in CRC cells.

Fig. 5
figure 5

CRART16 binds to miR-193b-5p as a ceRNA. a Schematic illustration of miR-193b-5p binding sequences in CRART16. b The dual luciferase reporter assay was performed to measure the luciferase activity after co-transfection of 293 T cells with miR-193b-5p mimics or NC and pmiR-RB-Report™-CRART16-WT vector or empty vector. *p < 0.05. c The expression levels of miR-193b-5p in CRART16-overexpressing CRC cells, SW620/5-FU cells and their corresponding control cells were measured by RT-qPCR. U6 was used as an internal reference. Data are presented as the mean ± SD from three independent experiments. **p < 0.01, ***p < 0.001. d, e The viability of SW620-CRART16 and Caco-2-CRART16 cells transfected with miR-193b-5p mimics or NC was detected by CCK-8 assay after treatment with stepwise increasing concentrations of 5-FU for 48 h. The IC50 values of 5-FU were calculated. *p < 0.05, **p < 0.01

Full size image

CRART16 sponges miR-193b-5p to modulate HMGA2 expression

Based on previous mRNA sequencing data and bioinformatics analysis results, we concentrated on HMGA2 as a potential target mRNA of miR-193b-5p. The binding sites between miR-193b-5p and the HMGA2 3′ untranslated region (UTR) predicted by TargetScan and RNAhybrid are displayed in Fig. 6a. The dual-luciferase reporter assay revealed that compared with the miRNA negative control group, overexpression of miR-193b-5p strikingly repressed the luciferase gene expression of HMGA2 3′ UTR reporter vectors while having little effect on empty vectors (Fig. 6b). The results indicated that HMGA2 was the target mRNA of miR-193b-5p. Subsequently, the expression levels of HMGA2 were assessed by RT-qPCR and western blotting. The results showed that HMGA2 expression was obviously upregulated in CRART16-overexpressing cells and SW620/5-FU cells (Fig. 6c, d). Furthermore, to detect whether CRART16 regulates HMGA2 expression via miR-193b-5p in CRC cells, a rescue experiment was performed and showed that introduction of miR-193b-5p mimics significantly attenuated HMGA2 protein levels in both SW620-CRART16 and Caco-2-CRART16 cells (Fig. 6e). Collectively, these results demonstrated that CRART16 sponges miR-193b-5p to upregulate HMGA2 expression in CRC cells.

Fig. 6
figure 6

CRART16 sponges miR-193b-5p to modulate HMGA2 expression. a Schematic illustration of miR-193b-5p binding sequences in the HMGA2 3′ UTR. b The dual luciferase reporter assay was performed to measure the luciferase activity after co-transfection of miR-193b-5p mimics or NC with pmiR-RB-Report™-HMGA2 3′ UTR-WT vector or empty vector in 293 T cells. *p < 0.05. c The mRNA expression levels of HMGA2 in CRART16-overexpressing CRC cells, SW620/5-FU cells and their corresponding control cells were determined by RT-qPCR. *p < 0.05, **p < 0.01. d The protein expression levels of HMGA2 in CRART16-overexpressing CRC cells, SW620/5-FU cells and their corresponding control cells were assessed by western blotting. e The protein expression levels of HMGA2 in SW620-CRART16 and Caco-2-CRART16 cells transfected with miR-193b-5p mimics or NC were assessed by western blotting

Full size image

CRART16 may inhibit 5-FU-induced apoptosis through the MAPK signaling pathway

In the present study, we demonstrated that CRART16 could promote 5-FU resistance in CRC cells by attenuating apoptosis. Western blotting further showed that CRART16 noticeably suppressed the levels of the apoptosis-related proteins cleaved PARP, cleaved caspase-3 and cleaved caspase-7 when exposed to 5-FU (Fig. 7a). In our previous study, based on RNA-seq, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, we found that the MAPK signaling pathway was obviously differentially enriched between Caco-2-CRART16 and Caco-2-NC cells [17]. In the present study, western blotting confirmed that the protein level of p-ERK was upregulated in both SW620-CRART16 and Caco-2-CRART16 cells (Fig. 7b), suggesting that the MAPK signaling pathway was activated by CRART16. Collectively, these results preliminarily showed that CRART16 attenuated 5-FU-induced apoptosis via the MAPK signaling pathway.

Fig. 7
figure 7

CRART16 activates the MAPK signaling pathway. a Cleaved and total PARP, caspase-3, caspase-7 levels were measured by western blotting. Tubulin was used as an internal reference. b ERK and p-ERK levels were measured by western blotting. GAPDH was used as an internal reference. c Schematic diagram of the mechanism of CRART16 in 5-FU resistance

Full size image

Discussion

In this study, we identified that lncRNA CRART16 expression was strikingly upregulated in 5-FU-resistant CRC cells. Functionally, we demonstrated that CRART16 promoted 5-FU resistance in CRC cells by attenuating apoptosis. Further mechanistic study revealed that CRART16 exerts its functions by sponging miR-193b-5p in CRC cells. In addition, CRART16 modulates the expression of HMGA2 by inhibiting miR-193b-5p and activates the MAPK signaling pathway.

In recent years, several studies have indicated that lncRNAs play a vital role in 5-FU resistance. For instance, H19 is upregulated in recurrent CRC tissues and contributes to 5-FU resistance by sponging miR-194-5p and then promoting SIRT1-mediated autophagy in CRC [19]. Conversely, it is downregulated and abates 5-FU resistance through the miR-193a-3p/PSEN1 axis in hepatocellular carcinoma [20]. HOTAIR confers 5-FU resistance by sponging miR-218 and activating NF-kB/TS signaling [21]. Our previous work first found that CRART16 promotes cetuximab resistance by enhancing ERBB3 expression by binding to miR-371a-5p in CRC cells [17]. In the present study, we focused on the role of CRART16 in 5-FU resistance in CRC and found that it was markedly upregulated in 5-FU-resistant cells. Moreover, after overexpression of CRART16, 5-FU sensitivity was sufficiently attenuated, as indicated by significantly decreased apoptosis, suggesting that CRART16 contributes to 5-FU resistance in CRC cells by decreasing apoptosis.

Recent studies have shown that lncRNAs can suppress the expression of miRNAs by acting as ceRNA sponges [22]. MiRNAs, a class of ncRNAs with lengths of 21–25 nucleotides [23], decrease the expression and thereby prevent the translation of their downstream target mRNAs by binding to complementary sequences located in the 3′ UTRs of mRNAs [24]. Over the past two decades, the crucial roles of miRNAs in cancer have been discovered [25]. It has emerged that miRNAs can participate in 5-FU resistance [26]. MiR-135b and miR-182 contribute to 5-FU resistance in CRC by deregulating ST6GALNAC2 and further activating the PI3K/AKT pathway [27]. In vitro and in vivo, overexpression of miR-15b-5p increases 5-FU-induced apoptosis and enhances 5-FU sensitivity by negatively regulating its NF-κB1 and IKK-α targets [28]. Previously, CRART16 was shown to promote cetuximab resistance by sponging miR-371a-5p in CRC cells [17]. Due to the upregulation and chemoresistance role of CRART16, it is reasonable to assume that CRART16 promotes 5-FU resistance by sponging a certain tumor suppressive miRNA. Our results revealed that the transcript levels of CRART16 and miR-193b-5p were negatively correlated in CRC cells. The direct binding relationship between them was validated by a dual-luciferase reporter assay. Several studies have indicated that miR-193b-5p can function as a tumor suppressive miRNA in different malignancies, including gastric cancer [29], acute myeloid leukemia [30], and breast cancer [31]. Consistently, in our study, rescue experiments demonstrated that overexpression of miR-193b-5p significantly reversed CRART16-induced 5-FU resistance in CRC cells.

Our study established that CRART16 upregulates the expression of HMGA2 by sponging miR-193b-5p in CRC cells. HMGA2, a member of the high-mobility group A (HMGA) gene family, encodes a small non-histone chromatin-associated protein without intrinsic transcriptional activity that can modulate transcription by remodeling the chromatin architecture [32, 33]. The HMGA2 protein is normally expressed abundantly during embryogenesis, but its expression is hard to detect in terminally differentiated tissues [32, 34]. Numerous studies have revealed that HMGA2 is overexpressed in many cancer cells [35], and overexpression of HMGA2 is correlated with progression and a poor prognosis in various malignancies, including CRC [36,37,38,39,40]. Furthermore, several studies have demonstrated that HMGA2 participates in 5-FU resistance in some malignancies, such as CRC [39, 41, 42], breast cancer [43, 44], and liver cancer [45]. For example, Zheng et al. [41] revealed that HMGA2 could promote 5-FU resistance, which could be reversed by miR-9-5p, in CRC cells. Wu et al. [39, 42] indicated that HMGA2 expression was upregulated by lncRNA PCAT6-mediated sponging of miR-204, ultimately contributing to 5-FU resistance in CRC cells, which could be reversed by silencing HMGA2. Consistently, in our study, we detected that HMGA2 was upregulated in 5-FU-resistant CRC cells and was modulated by the direct binding of CRART16 to miR-193b-5p. Taken together, we conclude that CRART16 contributes to the 5-FU resistance of CRC cells by upregulating HMGA2 expression by suppressing miR-193b-5p.

In this study, we found that CRART16 could inhibit apoptosis induced by 5-FU in CRC cells. Consequently, we tried to reveal the mechanism by which CRART16 modulates apoptosis. Based on previous works involving RNA-seq and GO enrichment and KEGG pathway analysis, we found that mRNAs in the MAPK signaling pathway were remarkably enriched in Caco-2-CRART16 cells versus Caco-2-NC cells [17]. Several studies have demonstrated that the ERK/MAPK signaling pathway might be an essential pathway of apoptosis in different malignancies [46,47,48]. Consistent with a present study, we found that the protein level of p-ERK was upregulated in CRART16-overexpressing CRC cells. Collectively, these results suggest that CRART16 could activate the MAPK signaling pathway to inhibit 5-FU-induced apoptosis in CRC cells. Intriguingly, overexpression of HMGA2 was found to upregulate the expression level of p-ERK in prostate cancer cells [49]. In addition, the downregulation of p-ERK by shPP4R1 transfection was restored by HMGA2 overexpression in non-small-cell lung cancer (NSCLC), whereas HMGA2 silencing attenuated the expression level of p-ERK induced by PP4R1 overexpression [50]. Overall, we concluded that CRART16 inhibits apoptosis induced by 5-FU through the MAPK signaling pathway modulated by HMGA2 in CRC cells.

Although there are still some limitations in our study, it provides a direction for following research. Only two cell lines were used in this study, which may have a certain influence on the extrapolation of the experimental results. We will carry out validation experiments on primary cells and perform in vivo experiments in the follow-up works.

Conclusions

In summary, CRART16 contributes to reducing the sensitivity of CRC cells to 5-FU by upregulating HMGA2 via suppression of miR-193b-5p, thereby activating the MAPK signaling pathway (Fig. 7c). Thus, CRART16 could be a promising therapeutic target for improving the effectiveness of 5-FU-based chemotherapy in CRC.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

CCK-8:

Cell counting kit-8

cDNA:

Complementary DNA

ceRNA:

Competing endogenous RNA

CRART16:

Cetuximab resistance-associated RNA transcript 16

CRC:

Colorectal cancer

DMEM:

Dulbecco’s Modified Eagle Medium

ERBB3:

V-Erb-B2 erythroblastic leukemia viral oncogene homologue 3

FBS:

Fetal bovine serum

GAPDH:

Glyceraldehyde 3-phosphate dehydrogenase

GO:

Gene Ontology

HMGA2:

High-mobility group AT-hook-2

KEGG:

Kyoto Encyclopedia of Genes and Genomes

LncRNAs:

Long noncoding RNAs

MAPK:

Mitogen-activated protein kinases

mCRC:

Metastatic colorectal cancer

NSCLC:

Non-small-cell lung cancer

PMSF:

Phenylmethylsulfonyl fluoride

PVDF:

Polyvinylidene fluoride

RT-qPCR:

Quantitative real-time PCR

TS:

Thymidylate synthase

3′ UTR:

3′ Untranslated region

5-FU:

5-Fluorouracil

7-AAD:

7-Amino-actinomycin D

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    PubMed  Google Scholar 

  2. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.

    PubMed  Google Scholar 

  3. Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-Fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206: 107447.

    CAS  PubMed  Google Scholar 

  4. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–6.

    CAS  PubMed  Google Scholar 

  5. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.

    CAS  PubMed  Google Scholar 

  6. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–7.

    PubMed  PubMed Central  Google Scholar 

  7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.

    CAS  PubMed  Google Scholar 

  8. Xie P, Mo JL, Liu JH, Li X, Tan LM, Zhang W, et al. Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update. Cell Oncol (Dordr). 2020;43:989–1001.

    CAS  Google Scholar 

  9. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–61.

    CAS  PubMed  Google Scholar 

  10. Yao N, Fu Y, Chen L, Liu Z, He J, Zhu Y, et al. Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene. 2019;38:7216–33.

    CAS  PubMed  Google Scholar 

  11. Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23:1331–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Xiong H, Ni Z, He J, Jiang S, Li X, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017;36:3528–40.

    CAS  PubMed  Google Scholar 

  13. Bian Z, Zhang J, Li M, Feng Y, Yao S, Song M, et al. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis. 2017;6:395.

    PubMed  PubMed Central  Google Scholar 

  14. Pan J, Li X, Wu W, Xue M, Hou H, Zhai W, et al. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 2016;382:64–76.

    CAS  PubMed  Google Scholar 

  15. Zeng L, Liao Q, Zou Z, Wen Y, Wang J, Liu C, et al. Long non-coding RNA XLOC_006753 promotes the development of multidrug resistance in gastric cancer cells through the PI3K/AKT/mTOR signaling pathway. Cell Physiol Biochem. 2018;51:1221–36.

    CAS  PubMed  Google Scholar 

  16. Wei L, Wang X, Lv L, Zheng Y, Zhang N, Yang M. The emerging role of noncoding RNAs in colorectal cancer chemoresistance. Cell Oncol (Dordr). 2019;42:757–68.

    CAS  Google Scholar 

  17. Zhang X, Wen L, Chen S, Zhang J, Ma Y, Hu J, et al. The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p. Cancer Cell Int. 2020;20:68.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.

    CAS  Google Scholar 

  19. Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9:1149.

    PubMed  PubMed Central  Google Scholar 

  20. Ma H, Yuan L, Li W, Xu K, Yang L. The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1. J Cell Biochem. 2018;119:8325–35.

    CAS  PubMed  Google Scholar 

  21. Li P, Zhang X, Wang L, Du L, Yang Y, Liu T, et al. lncRNA HOTAIR contributes to 5FU resistance through suppressing miR-218 and activating NF-κB/TS signaling in colorectal cancer. Mol Therapy Nucleic Acids. 2020;20:879–80.

    CAS  Google Scholar 

  22. Rashid F, Shah A, Shan G. Long non-coding RNAs in the cytoplasm. Genom Proteom Bioinform. 2016;14:73–80.

    Google Scholar 

  23. Lee RC, Ambros V. An extensive class of small RNAs in caenorhabditis elegans. Science (New York, NY). 2001;294:862–4.

    CAS  Google Scholar 

  24. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.

    CAS  PubMed  Google Scholar 

  25. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Marjaneh RM, Khazaei M, Ferns GA, Avan A, Aghaee-Bakhtiari SH. The role of microRNAs in 5-FU resistance of colorectal cancer: possible mechanisms. J Cell Physiol. 2019;234:2306–16.

    CAS  PubMed  Google Scholar 

  27. Liu B, Liu Y, Zhao L, Pan Y, Shan Y, Li Y, et al. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Mol Carcinog. 2017;56:2669–80.

    CAS  PubMed  Google Scholar 

  28. Zhao C, Zhao Q, Zhang C, Wang G, Yao Y, Huang X, et al. miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis. Sci Rep. 2017;7:4194.

    PubMed  PubMed Central  Google Scholar 

  29. Hu H, Kong Q, Huang XX, Zhang HR, Hu KF, Jing Y, et al. Longnon-coding RNA BLACAT2 promotes gastric cancer progression via the miR-193b-5p/METTL3 pathway. J Cancer. 2021;12:3209–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, et al. Endogenous tumor suppressor microRNA-193b: therapeutic and prognostic value in acute myeloid leukemia. J Clin Oncol. 2018;36:1007–16.

    CAS  PubMed  Google Scholar 

  31. Hu S, Cao M, He Y, Zhang G, Liu Y, Du Y, et al. CD44v6 targeted by miR-193b-5p in the coding region modulates the migration and invasion of breast cancer cells. J Cancer. 2020;11:260–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004;574:1–8.

    CAS  PubMed  Google Scholar 

  33. Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007;17:72–9.

    CAS  PubMed  Google Scholar 

  34. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene. 2001;277:63–81.

    CAS  PubMed  Google Scholar 

  35. Zhang S, Mo Q, Wang X. Oncological role of HMGA2 (review). Int J Oncol. 2019;55:775–88.

    CAS  PubMed  Google Scholar 

  36. Zhang M, Hu D, Wang S, Qin C. Clinicopathologic significance of HMGA2 expression’s correlation with prognosis of esophageal squamous cell carcinoma after Ivor Lewis esophagectomy. Minerva Chir. 2016;71:239–44.

    PubMed  Google Scholar 

  37. Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505:212–7.

    CAS  PubMed  Google Scholar 

  38. Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F, Zimmermann A, et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology. 2012;60:397–404.

    PubMed  Google Scholar 

  39. Wu H, Liang Y, Shen L, Shen L. MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2. Biol Open. 2016;5:563–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 2011;17:2570–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Zheng H, Yan B, Wu Q, Zhang J. MicroRNA-9-5p increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating high mobility group A2 expression. Oncol Lett. 2021;21:235.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Wu H, Zou Q, He H, Liang Y, Lei M, Zhou Q, et al. Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med. 2019;8:2484–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Li X, Wang S, Li Z, Long X, Guo Z, Zhang G, et al. The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol. 2017;105:346–53.

    CAS  PubMed  Google Scholar 

  44. Zhu M, Wang Y, Wang F, Li L, Qiu X. CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b/HMGA2 axis. Cancer Cell Int. 2021;21:384.

    PubMed  PubMed Central  Google Scholar 

  45. Tang H, Zhang P, Xiang Q, Yin J, Yu J, Yang X, et al. Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. Pharmazie. 2014;69:287–92.

    CAS  PubMed  Google Scholar 

  46. Yue J, Jin S, Gu S, Sun R, Liang Q. High concentration magnesium inhibits extracellular matrix calcification and protects articular cartilage via Erk/autophagy pathway. J Cell Physiol. 2019;234:23190–201.

    CAS  PubMed  Google Scholar 

  47. Gao L, Dou ZC, Ren WH, Li SM, Liang X, Zhi KQ. CircCDR1as upregulates autophagy under hypoxia to promote tumor cell survival via AKT/ERK(½)/mTOR signaling pathways in oral squamous cell carcinomas. Cell Death Dis. 2019;10:745.

    PubMed  PubMed Central  Google Scholar 

  48. Xiong Q, Liu A, Ren Q, Xue Y, Yu X, Ying Y, et al. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer. Cell Death Dis. 2020;11:366.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Hawsawi O, Henderson V, Burton LJ, Dougan J, Nagappan P, Odero-Marah V. High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer. Biochem Biophys Res Commun. 2018;504:196–202.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Wang B, Pan LY, Kang N, Shen XY. PP4R1 interacts with HMGA2 to promote non-small-cell lung cancer migration and metastasis via activating MAPK/ERK-induced epithelial-mesenchymal transition. Mol Carcinog. 2020;59:467–77.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge Dr. Dingfang Bu for technical support and Dr. Yongrui Jia for conducting flow cytometry analysis.

Funding

Not applicable.

Author information

Author notes

  1. Jingui Wang and Xiaoqian Zhang contributed equally to this work

Authors and Affiliations

  1. Department of General Surgery, Peking University First Hospital, NO. 8 Xishiku Street, Xicheng, Beijing, 100034, People’s Republic of China

    Jingui Wang, Xiaoqian Zhang, Junling Zhang, Shangwen Chen, Jing Zhu & Xin Wang

  2. Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, No. 17, Panjiayuan Nanli, Chaoyang, Beijing, 100021, People’s Republic of China

    Xiaoqian Zhang

Authors
  1. Jingui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoqian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junling Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shangwen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XW was the major contributor to the design of this study and revised the manuscript. JW participated in the design of the study, cytology experiments, statistical analyses and writing the manuscript. XZ participated in the design of the study, cytology experiments, statistical analyses and revised the manuscript. JZ, JLZ and SC participated in the design of the study and provided technical guidance. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xin Wang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Zhang, X., Zhang, J. et al. Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p. Cancer Cell Int 21, 638 (2021). https://doi.org/10.1186/s12935-021-02353-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-021-02353-5

Keywords

  • Long noncoding RNA
  • CRART16
  • 5-FU
  • Resistance
  • miR-193b-5p
  • HMGA2
  • MAPK

Cancer Cell International

ISSN: 1475-2867

Contact us